Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (3): 548-551. doi: 10.19723/j.issn.1671-167X.2022.03.022

Previous Articles     Next Articles

Effect of artificial liver with double plasma molecular absorb system model on patients' platelets and corresponding treatment strategy

Jin-feng JIA,Fei LIANG*(),Jian-wei HUANG,Hao WANG,Pu-qing HAN   

  1. Department of Gastroenterology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
  • Received:2021-04-29 Online:2022-06-18 Published:2022-06-14
  • Contact: Fei LIANG E-mail:ucbzuhy@163.com
  • Supported by:
    Guangdong Medical Science and Technology Research Foundation Project(A2020634)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To compare the effects of artificial liver treatment with double plasma molecular adsorption system(DPMAS) mode and traditional plasma exchange (PE) mode on platelets in patients, and to evaluate the clinical efficacy of recombinent human thrombopoietin (rhTPO) in the treatment of thrombocytopenia. Methods: A total of fifteen patients undergoing artificial liver with DPMAS model admitted to the Fifth Affiliated Hospital of Guangzhou Medical University from January 2018 to November 2020 were selected and included in the DPMAS group, and another 15 patients receiving PE were selected and included in the PE group. The improvement of clinical symptoms, such as fatigue, jaundice, oliguria, edema, etc. before and after artificial liver treatment was compared between the two groups, and the trend of blood routine (especially platelet), coagulation function and other indexes before and after treatment were compared between the two groups. The use of rhTPO and the number of platelets were recorded during treatment. Results: The improvement rate of clinical symptoms in DPMAS group was 86.67%, which was higher than that in PE group, but the difference was not statistically significant (P>0.05). There was no statistical significance in the outcome of the two groups within 90 days (P>0.05). There was no significant difference in white blood cell (WBC) and hemoglobin (HB) between the two groups after treatment (P>0.05). However, the level of platelet(PLT) in DPMAS group was significantly lower than that before treatment (P < 0.05), and was significantly lower than that in PE group (P < 0.05). After treatment, the international normalized ratio (INR) level in PE group was significantly improved (P < 0.05), but there was no significant difference in the INR level in DPMAS group (P>0.05). The patients in the DPMAS group received an average of (8.2±3.1) doses of rhTPO and (1.5±0.3) IU of platelet transfusions during hospitalization. In DMPAS group, platelets increased significantly after infusion of terbium. Conclusion: Compared with PE mode, the artificial liver with DPMAS mode can reduce platelet levels in patients, but the application of rhTPO can stimulate platelet regeneration and increase platelet levels in the patients, thereby reducing the risk of bleeding due to platelet hypoplasia.

Key words: Artificial liver, Dual plasma molecular adsorption system, Plasmapheresis, Platelets, Recombinant human thrombopoietin (rhTPO)

CLC Number: 

  • R575.3

Table 1

Comparison of blood routine and coagulation function indexes between the two groups that before and after treatment"

Items PE group (n=15) DPMAS group (n=15) t value P value
WBC/(×109/L) Before treatment 5.68±2.31 5.31±1.98 0.471 0.641
After treatment 6.42±1.83 5.98±2.31 0.578 0.568
Hb/(g/L) Before treatment 10.93±3.23 9.98±2.87 0.852 0.402
After treatment 7.58±2.31* 8.91±2.19* 1.618 0.117
PLT/(×109/L) Before treatment 95.48±11.29 96.51±21.15 0.166 0.869
After treatment 87.31±21.38* 51.02±17.11* 5.133 0.000
INR Before treatment 2.84±0.37 2.97±0.54 0.769 0.448
After treatment 1.47±0.76* 2.85±0.73 5.072 0.000

Table 2

Comparison of biochemical indexes between the two groups that before and after treatment"

Items PE group (n=15) DPMAS group (n=15)
ALT/(U/L) Before treatment 267.33±32.35 259.39±31.78
After treatment 87.52±21.76* 85.90±22.39*
AST/(U/L) Before treatment 180.96±33.43 189.92±32.85
After treatment 77.23±12.36* 88.97±22.10*
TBil/(μmol/L) Before treatment 339.42±44.21 347.50±38.19
After treatment 235.57±27.53* 207.42±26.10*

Figure 1

Changes of platelet (PLT) levels in DPMAS group that before and after used rhTPO Red arrow, start time of infusion of recombinant human thrombopoietin."

1 Stravitz RT , Lee WM . Acute liver failure[J]. Lancet, 2019, 394 (10201): 869- 881.
doi: 10.1016/S0140-6736(19)31894-X
2 Dong V , Nanchal R , Karvellas CJ . Pathophysiology of acute liver failure[J]. Nutr Clin Pract, 2020, 35 (1): 24- 29.
doi: 10.1002/ncp.10459
3 Kok B , Dong V , Karvellas CJ . Graft dysfunction and management in liver transplantation[J]. Crit Care Clin, 2019, 35 (1): 117- 133.
doi: 10.1016/j.ccc.2018.08.002
4 Larsen FS . Artificial liver support in acute and acute-on-chronic liver failure[J]. Curr Opin Crit Care, 2019, 25 (2): 187- 191.
doi: 10.1097/MCC.0000000000000584
5 Larsen FS , Schmidt LE , Bernsmeier C , et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64 (1): 69- 78.
doi: 10.1016/j.jhep.2015.08.018
6 Wan YM , Li YH , Xu ZY , et al. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: A prospective study[J]. J Clin Apher, 2017, 32 (6): 453- 461.
doi: 10.1002/jca.21535
7 García Martínez JJ , Bendjelid K . Artificial liver support systems: What is new over the last decade[J]. Ann Intensive Care, 2018, 8 (1): 109.
doi: 10.1186/s13613-018-0453-z
8 Huang K , Ji F , Xie Z , et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis[J]. Sci Rep, 2019, 9 (1): 16462.
doi: 10.1038/s41598-019-53029-0
9 Wu G , Wu D , Lo J , et al. A bioartificial liver support system integrated with a DLM/GelMA-based bioengineered whole liver for prevention of hepatic encephalopathy via enhanced ammonia reduction[J]. Biomater Sci, 2020, 8 (10): 2814- 2824.
doi: 10.1039/C9BM01879D
10 Gundamaraju R , Vemuri R , Chong WC , et al. Bilirubin attenuates ER stress-mediated inflammation, escalates apoptosis and reduces proliferation in the LS174T colonic epithelial cell line[J]. Int J Med Sci, 2019, 16 (1): 135- 144.
doi: 10.7150/ijms.29134
11 Lee Y , Sugihara K , Gillilland MG 3rd , et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis[J]. Nat Mater, 2020, 19 (1): 118- 126.
doi: 10.1038/s41563-019-0462-9
12 Yao J , Li S , Zhou L , et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34 (4): 392- 398.
doi: 10.1002/jca.21690
13 农村立, 郭堑, 韦秋芳, 等. 双重血浆分子吸附系统序贯血浆置换治疗肝衰竭的临床疗效[J]. 现代医药卫生, 2018, 34 (12): 22- 24.
14 Tang B , Huang L , Liu H , et al. Recombinant human thrombo-poietin promotes platelet engraftment after umbilical cord blood transplantation[J]. Blood Adv, 2020, 4 (16): 3829- 3839.
doi: 10.1182/bloodadvances.2020002257
15 Zhang J , Lu Z , Xiao W , et al. Efficacy and safety of recombinant human thrombopoietin on sepsis patients with thrombocytopenia: A systematic review and meta-analysis[J]. Front Pharmacol, 2020, 11 (3): 940.
[1] Hong-yu GAO,Jing-ling XU,Huan-xin MENG,Lu HE,Jian-xia HOU. Effect of initial periodontal therapy on blood parameters related to erythrocyte and platelet in patients with type 2 diabetes mellitus and chronic periodontitis [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 750-754.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd